Mogamulizumab-kpkc

(Poteligeo®)

Mogamulizumab-kpkc

Drug updated on 10/29/2024

Dosage FormInjection (intravenous: 20 mg/5 mL [4 mg/mL])
Drug ClassCC chemokine receptor type 4 (CCR4)-directed monoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Szary syndrome after at least one prior systemic therapy.

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of two systematic review(s)/meta-analysis(es). [1-2]
  • The MAVORIC trial indicated that mogamulizumab (Poteligeo) demonstrated favorable outcomes in patients with mycosis fungoides (MF) and Sézary syndrome (SS) compared to vorinostat, although the trial's crossover design introduces uncertainty into these results.
  • A systematic review of 20 randomized controlled trials (RCTs) showed a wide variability in effectiveness outcomes for various interventions in MF, with complete response (CR) rates ranging from 0% to 83% and objective response rates (ORR) from 0% to 88%.
  • The evidence comparing mogamulizumab to treatments like methotrexate, bexarotene, and vorinostat was limited and of low certainty, mainly due to study design flaws and small sample sizes, emphasizing the need for caution in interpreting these comparisons.
  • There is no safety information available in the reviewed studies.
  • There is no population types or subgroups information available in the reviewed studies.

Product Monograph / Prescribing Information

Document TitleYearSource
Poteligeo (mogamulizumab-kpkc) Prescribing Information.2023Kyowa Kirin, Inc., Princeton, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review2024Journal of the European Academy of Dermatology and Venereology
Interventions for mycosis fungoides2020The Cochrane Database of Systematic Reviews

Clinical Practice Guidelines